Neurorehabilitation News

The FDA has granted orphan drug designation to Avidity Biosciences Inc. for AOC 1020, its novel RNA therapeutic to treat facioscapulohumeral muscular dystrophy.

Cerebral amyloid angiopathy was associated with a higher risk for isolated nontraumatic subdural hemorrhage in two large, independent cohorts, according to research presented at International Stroke Conference.

Recurrent stroke risk has declined over the past 2 decades, with women experiencing a twofold decline compared with men, according to preliminary research presented at the International Stroke Conference.

Athira Pharma Inc. revealed its list of planned clinical trials for 2023, which include development of therapeutics for Alzheimer’s disease, Parkinson’s disease and ALS.

With a rising number of clinical studies demonstrating the potential benefits of psychedelic treatments for a wide range of behavioral health conditions, insurance plan provider Enthea aims to expand employer funding for these services.

Amylyx Pharmaceuticals Inc. announced completion of enrollment for a global, phase 3 clinical trial of AMX0035, an oral, fixed-dose medication for ALS.

Although well-tolerated with few adverse events, treatment with leriglitazone did not slow disease progression in men with adrenomyeloneuropathy compared with placebo, per a study published in Lancet Neurology.

Alto Neuroscience Inc. announced that Alpha Wave Ventures has made a $25 million equity investment to its Series B funding, bringing the total to roughly $60 million as Alto seeks to expand its roster of mental-health related therapeutics.

The incidence of frontotemporal labor degeneration-associated disorders is more common in Europe than previously thought, with an estimated 12,057 new cases per year, researchers reported in JAMA Neurology.

Researchers recently found that the pharmacokinetic properties of vesicular monoamine transporter 2 inhibitors may play a role in the treatment of tardive dyskinesia.